Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
Subscribe To Our Newsletter & Stay Updated
